114 related articles for article (PubMed ID: 36733049)
1. [Eight Cases of Breast Cancer That Relapsed More Than Ten Years after Initial Treatment].
Yoshimura A; Ueda T; Tanaka T; Kirihataya Y; Soga M; Yokotani T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1935-1937. PubMed ID: 36733049
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Venkatesan V; Dar AR; Stitt L
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):541-50. PubMed ID: 9231678
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
6. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
7. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
8. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
10. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.
Wangchinda P; Ithimakin S
World J Surg Oncol; 2016 Aug; 14(1):223. PubMed ID: 27557635
[TBL] [Abstract][Full Text] [Related]
11. Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience.
Cvetanovic A; Filipovic S; Zivkovic N; Popovic L; Kostic M; Djordjevic M; Karanikolic A; Krtinic D
J BUON; 2018; 23(2):353-360. PubMed ID: 29745076
[TBL] [Abstract][Full Text] [Related]
12. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
Kilbride KE; Lee MC; Nees AV; Cimmino VM; Diehl KM; Sabel MS; Hayes DF; Schott AF; Kleer CG; Chang AE; Newman LA
Ann Surg Oncol; 2008 Nov; 15(11):3252-8. PubMed ID: 18784961
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
14. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
15. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
17. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.
Tai CJ; Pan CK; Chen CS; Hung CS; Wu CH; Chiou HY
Asian Pac J Cancer Prev; 2013; 14(3):1981-4. PubMed ID: 23679303
[TBL] [Abstract][Full Text] [Related]
19. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
[TBL] [Abstract][Full Text] [Related]
20. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
Chen X; Fan Y; Xu B
Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
